Navigation Links
First biomarker discovered that predicts prostate cancer outcome
Date:8/14/2007

, more research is necessary. Mayo is planning clinical trials for a number of cancers in late 2008, and researchers are currently developing the necessary therapeutic antibodies to be used in these studies. Investigators expect that clinical laboratory tests for the B7-H proteins may become available at Mayo to assist with the assessment of patients with kidney cancer by late 2007 or early 2008, and then for prostate cancer patients shortly thereafter.

Unique Mayo Registry Key

This study was possible because of Mayos unique patient registry for prostate cancer. The registry contains hundreds of discrete pieces of information, ranging from environmental factors to specific medical test results, for more than 15,000 prostate cancer patients, all followed prospectively since the first patient was entered into the database in 1970. The Mayo Clinic prostate cancer and kidney cancer registries represent the most detailed and complete cancer reference tools in the world. Using the latter registry, Mayo investigators were previously able to link high levels of another B7-H molecule, B7-H1, to poor kidney cancer outcomes, including significantly shortened survival times.

Without the key road maps provided by these registries, the recognition of important molecules that drive cancer would not be feasible, say the researchers. Use of these patient registries enables laboratory science to be directly linked to patient care and survival following treatment.

To a large extent, working with these registries dramatically lessens the time, resources and effort that are required to link a candidate molecule to its role in cancer development and progression, says Dr. Kwon, who is also the co-director of the Cancer Immunology and Immunotherapy Program in Mayo Clinic Cancer Center. Our studies are the very first to provide a clear link between immune molecules and the behaviors of various cancers.

Dr. Kwon and his fellow researchers
'/>"/>

Contact: Elizabeth Zimmermann
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. First Vaccine Designed for Africa Cleared for Testing in Humans
2. Infant receives first bloodless liver transplant
3. Oracle Corp. to help build worlds first "Digital Hospital"
4. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
5. First human clone is near
6. First Artificial Heart patient has Major setback
7. First global SARS meet opens
8. Launch Of India’s First Virology Course At Pun
9. FDA approves first pocket-sized EKG machine
10. First head-to-head trials of once weekly Fosamax and Actonel therapies
11. WHO Declares Vietnam First Country to Control SARS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for
(Date:12/4/2009)NEW YORK, Dec. 4 Care Investment Trust Inc. (NYSE: CRE ) ("Care" or the "Company") today announced that its Board of Directors has declared a dividend of $0.17 per share of common stock. The div
(Date:12/4/2009)SCOTTSDALE, Ariz., Dec. 4 Healthcare Trust of America, Inc. ("HTA"), a self-managed, non-traded, real estate investment trust, announced the execution of a purchase and sale agreement to acquire a th
(Date:12/4/2009)WASHINGTON, Dec. 4 In response to the U.S. Justice Department Drug Enforcement Agency,s (DEA) classification of boldione, desoxymethyltestosterone, and 19-nor-4,9(10)-androstadienedione as "anabolic
(Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa
Breaking Medicine News(10 mins):Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2Health News:Natural Products Association Issues Statement on DEA's Steroid Classification Action 2Health News:Human guinea pigs wary of high-paying medical trials 2
... cases at the Brisbane studios of Australian Broad...ern among its staff. Former news assistant...e among the ABC staff who worked at the now-abando...f compensation for those diagnosed with the diseas...
...e into claims that Paris Hilton received preferent...cility last month. Rumours were rife that t...of probation, was given several privileges by the ...rm instead of a recycled one given to other inmate...
... at a pal's home after her break-up with troubled ...ermodel is staying with celebrity hairdresser and ... Babyshambles frontman's infidelity. Moss ...rned a collection of love letters and poetry which...
...s Center have revealed that genes play a large rol...aste perception. The findings may help re...r that detects sourness in foods and beverages, ju...ds in foods and beverages. In fact, the word acid ...
...ly approved a plan to give families 2,500 euros (3...flagging birth rate . First Deputy Prime M...lowing Friday's cabinet meeting the measure would ...amilies who have had children, including adopted i...
...as urged its six million "sexually active" citizen...ational campaign starts Monday . Health au...tatistics had shown that out of "six million sexua...ow that they are carrying the virus because they h...
Other Medicine News:Health News:More Cancer Testing Urged in Australian TV Studios 2Health News:More Cancer Testing Urged in Australian TV Studios 3Health News:Genes Play Major Role in Determining Individual's Sour Taste Perception 2
(Date:12/3/2009)DOYLESTOWN, Pa., Dec. 3 Ted Karkus, Chairman and CEO of The Quigley Corporation, (Nasdaq: QGLY ) www.quigleyco.com announced today that the Company has completed its evaluation of its opportunitie
(Date:12/3/2009)WARRENDALE, Pa., Dec. 3 Radiology imaging leader MEDRAD, Inc. demonstrated PACS* injection-record integration capabilities at the November 2009 Radiology Society of North America in Chicago. The Co
(Date:12/3/2009)HOERSHOLM, Denmark and SAN DIEGO, California, December 3 , - SPC3649 Successfully Inhibits miR-122, a microRNA Important for,Hepatitis C Viral Replication, Thereby Significantly Reducing Hepatiti
Breaking Medicine Technology:Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5California Cancer Specialists Medical Group Inc finds clinical benefit in RapidArc 28TM 29 technology and executes strategic vendor agreement with V 58392 1California Cancer Specialists Medical Group Inc finds clinical benefit in RapidArc 28TM 29 technology and executes strategic vendor agreement with V 58392 2Illinois based AthletiCo Opens 53rd Physical Therapy Center in Elk Grove Village 58387 1Illinois based AthletiCo Opens 53rd Physical Therapy Center in Elk Grove Village 58387 2Illinois based AthletiCo Opens 53rd Physical Therapy Center in Elk Grove Village 58387 3Winnick Family Scholarship Awarded to Ramona Davoudpour at UCLA School of Medicine 58383 1Winnick Family Scholarship Awarded to Ramona Davoudpour at UCLA School of Medicine 58383 2Winnick Family Scholarship Awarded to Ramona Davoudpour at UCLA School of Medicine 58383 3Winnick Family Scholarship Awarded to Ramona Davoudpour at UCLA School of Medicine 58383 4
Finnpipette Fixed Volume, 20ul
Pipetman F1000
Finnpipette Focus Fixed Volume, 1ul
Finnpipette Fixed Volume, 2ul
Medicine Products: